Candel Therapeutics (NASDAQ: CADL) has announced the appointment of internationally recognized expert in systems immunology and vaccinology, Bali Pulendran, PhD, to Candel’s research advisory board.
Dr. Pulendran is the Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection at Stanford University and a Fellow at ChEM-H (Chemistry, Engineering and Medicine for Human Health).
In a statement, Dr. Pulendran, commented, “I’m honored to join Candel’s research advisory board during this pivotal stage for the company. Candel’s innovative viral immunotherapy platform represents a compelling approach to activating the immune system against cancer. I look forward to contributing my experience in systems immunology and understanding immune responses to help advance these promising therapies that have the potential to benefit patients across multiple cancer types.”
Paul Peter Tak, MD, PhD, FMedSci, president and CEO of Candel, added, “We are excited to welcome Dr. Pulendran to our research advisory board. His pioneering work in systems immunology and his deep understanding of how the immune system responds to various stimuli will provide invaluable insights as we continue to advance CAN-2409 across multiple solid tumors and CAN-3110 in recurrent high-grade glioma, developing potentially vital therapies to those who need them most.”
